South Korean pharmaceutical and biotech companies are on track to exceed 10 trillion won ($7.5 billion) in licensing revenues ...

FDA approvals for new biosimilars like Starjemza and Hadlima enhance treatment options, addressing urgent needs for ...

The U.S. federal court ruling that President Trump had overstepped his authority on imposing tariffs marked a clear setback ...

Despite regulation changes in the Chinese healthcare industry, we think CSPC is well-positioned to maintain relatively strong revenue growth. First, generic drugs normally face the most severe price ...

Notably, the U.S.’ two primary biopharma trade groups—the Pharmaceutical Research and Manufacturers of America (PhRMA) and ...

FRANKFURT, Germany, May 29, 2025 /CNW/ -- Qualifyze, already the global leader in third-party audit services for the ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the ...

The administration of US President Donald Trump has taken a series of actions since January, 2025 that directly threaten the ...

Pharma company stocks tumbled after Donald Trump announced a plan to reduce U.S. drug prices, but regained some ground on belief the plan would be hard to implement Drug prices are expected to decline ...

While the Trump administration’s threat of pharmaceutical import tariffs and most favored nation (MFN) drug pricing has ...

How unfortunate if taxes restrain the global cooperation so essential to progress, including life-saving cures.

Akums Drugs and Pharmaceuticals Ltd., India's leading CDMO, reported a 12.4% YoY revenue growth in Q4 FY25 with a focus on ...